rosiglitazone has been researched along with chenodeoxycholic acid in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
| Antonelli, E; Fiorucci, S; Mencarelli, A; Morelli, A; Pellicciari, R; Pruzanski, M; Renga, B; Riccardi, L; Rizzo, G | 1 |
| Distrutti, E; Fiorucci, S; Mencarelli, A; Renga, B | 1 |
| Cipriani, S; Fiorucci, S; Mencarelli, A; Palladino, G | 1 |
| He, JG; Lu, XH; Lv, GP; Si, SY; Zhang, H; Zhao, BH; Zheng, ZH | 1 |
| Akanuma, N; Akutsu, Y; Hanari, N; Hoshino, I; Isozaki, Y; Maruyama, T; Matsubara, H; Mori, M; Murakami, K; Nakayama, T; Nishimori, T; Suito, H; Suzuki, A; Takahashi, M; Takeshita, N; Toyozumi, T | 1 |
| Allen, AM; Khera, R; Loomba, R; Murad, MH; Singh, S | 1 |
3 review(s) available for rosiglitazone and chenodeoxycholic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
Topics: Chenodeoxycholic Acid; Drug Therapy, Combination; Humans; Non-alcoholic Fatty Liver Disease; Pioglitazone; Publication Bias; Rosiglitazone; Thiazolidinediones; Vitamin E | 2015 |
9 other study(ies) available for rosiglitazone and chenodeoxycholic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.
Topics: Animals; Cells, Cultured; Chenodeoxycholic Acid; DNA-Binding Proteins; Gene Expression Regulation; Humans; Liver; Liver Cirrhosis, Experimental; PPAR gamma; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2005 |
Antiatherosclerotic effect of farnesoid X receptor.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cardiovascular Agents; CD11b Antigen; CD36 Antigens; Chenodeoxycholic Acid; Disease Models, Animal; DNA-Binding Proteins; Female; Humans; Hyperlipidemias; Interleukin-1beta; Interleukin-6; Ligands; Lipids; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR gamma; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Toll-Like Receptor 4; Transcription Factors; Tumor Necrosis Factor-alpha | 2009 |
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.
Topics: Animals; Chenodeoxycholic Acid; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Gene Expression Regulation; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Male; Muscle, Skeletal; Obesity; Phosphorylation; Random Allocation; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors | 2010 |
Impacts of different promoters on the mammalian one-hybrid assay for detecting nuclear receptor agonists.
Topics: Animals; Bezafibrate; Cells, Cultured; Chenodeoxycholic Acid; Drug Discovery; Genetic Vectors; HeLa Cells; High-Throughput Screening Assays; Humans; Hydrocarbons, Fluorinated; Ligands; Mice; NIH 3T3 Cells; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Promoter Regions, Genetic; Pyrimidines; Rosiglitazone; Sensitivity and Specificity; Structure-Activity Relationship; Sulfonamides; Thiazolidinediones; Two-Hybrid System Techniques | 2010 |
Screening of alternative drugs to the tumor suppressor miR-375 in esophageal squamous cell carcinoma using the connectivity map.
Topics: Antineoplastic Agents; Apoptosis; Benzocaine; Betazole; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Chenodeoxycholic Acid; Cytotoxins; DNA Primers; Esophageal Neoplasms; Humans; In Situ Nick-End Labeling; Metformin; MicroRNAs; Nizatidine; Organophosphates; Proline; Protein Array Analysis; Real-Time Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Transcriptome; Transfection; Tumor Suppressor Proteins | 2014 |